Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Cytokine-induced Killer Study for Patients With Stage II Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 300
- Registration Number
- NCT02498756
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT02498600
- Locations
- 🇺🇸
Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States
🇺🇸Sutter Davis Hospital, Davis, California, United States
🇺🇸Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
- Conditions
- Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage III Bladder Cancer AJCC v8Stage III Urethral Cancer AJCC v8Bladder Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaStage III Renal Pelvis Cancer AJCC v8Stage IV Penile Cancer AJCC v8
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 152
- Registration Number
- NCT02496208
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 578
- Registration Number
- NCT02488759
- Locations
- 🇺🇸
Local Institution - 0003, Atlanta, Georgia, United States
🇧🇪Local Institution - 0012, Brussels, Belgium
🇺🇸Local Institution - 0033, Tampa, Florida, United States
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2748
- Registration Number
- NCT02477826
- Locations
- 🇺🇸
Local Institution - 0017, San Francisco, California, United States
🇺🇸Local Institution - 0115, Saint Louis, Missouri, United States
🇺🇸Local Institution - 0014, Cleveland, Ohio, United States
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02467361
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT02453620
- Locations
- 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Rabih Said
- Registration Number
- NCT02452281
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT02428192
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Alden Cancer Therapy II
- Target Recruit Count
- 18
- Registration Number
- NCT02423928
- Locations
- 🇳🇴
Haukeland University Hospital Research Department, Bergen, Hordaland, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.